STTK
Shattuck Labs, Inc.2.9400
-0.1200-3.92%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
186.04MP/E (TTM)
-Basic EPS (TTM)
-0.99Dividend Yield
0%Recent Filings
8-K
Shattuck advances SL-325 trial
Shattuck Labs dosed first participants in the Phase 1 trial of SL-325, its lead DR3 antagonist for IBD, in Q3 2025, while closing an up-to-$103 million private placement in August to fund operations into 2029. Cash stood at $86.1 million as of September 30, down from $90.1 million a year prior, with R&D expenses dropping to $7.6 million from $16.3 million, narrowing net loss to $10.1 million. The company appointed Dan Baker, M.D., and Mona Ashiya, Ph.D., to its board. Phase 1 data expected in Q2 2026.
10-Q
Q3 FY2025 results
Shattuck Labs narrowed its Q3 net loss to $10.1 million from $16.7 million a year earlier, driven by a 53% drop in R&D spending to $7.6 million after discontinuing SL-172154 and trimming staff, while revenue dipped to $1.0 million from a $3.0 million Ono collaboration payout, offset by a Kayak license deal. Year-to-date, the net loss shrank 36% to $36.2 million on $1.0 million revenue versus $5.7 million last year, with R&D expenses falling 49% to $26.2 million as SL-325 advances to Phase 1 trials. Cash burn eased, leaving $86.1 million in cash and equivalents at quarter-end, bolstered by $44.5 million from an August equity raise including warrants. No debt weighs on the balance sheet. Yet regulatory delays from the ongoing government shutdown pose a key risk.
8-K
Shattuck closes $103M placement
Shattuck Labs closed its $103 million private placement on August 25, 2025, led by OrbiMed, with proceeds expected to fund operations into 2029 and advance SL-325 through multiple Phase 2 trials in inflammatory bowel disease and other autoimmune conditions. Four directors resigned without disagreement, while the board appointed immunology expert Dr. Daniel Baker and OrbiMed's Dr. Mona Ashiya, each receiving 66,300 vesting stock options. This repositions Shattuck as an immunology-focused biotech. Warrants may add capital, but exercise remains uncertain.
8-K
IND submitted for SL-325
Shattuck Labs submitted an IND for SL-325, its lead DR3 blocker for IBD, in July 2025, eyeing Phase 1 dosing in healthy volunteers this quarter and completion by Q2 2026. Cash stood at $50.5 million as of June 30, 2025, down from $105.3 million a year ago, while R&D expenses dropped to $8.7 million from $19.2 million, trimming net loss to $12.5 million. An oversubscribed $103 million private placement, contingent on IND clearance, will extend runway into 2029. Funding secured.
10-Q
Q2 FY2025 results
Shattuck Labs narrowed its Q2 net loss to $12.5M from $21.6M a year earlier, thanks to slashed R&D spending after ditching SL-172154 and wrapping up collaborations with Ono and ImmunoGen that drove $1.6M in prior revenue. Research costs dropped 55% year-over-year to $8.7M, with SL-325 ramping up to $2.6M as the lead program advances toward Phase 1 trials in Q3 2025. Cash burn eased, leaving $50.5M in cash and equivalents at quarter-end, sufficient into 2027, bolstered by a pending $46M private placement tied to SL-325's IND clearance. No debt weighs on the balance sheet. Yet Nasdaq delisting looms if the stock can't hold $1 for 10 straight days by February 2026.